• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
From "Ought" to "Is": Surfacing Values in Patient and Family Advocacy in Rare Diseases.从“应当”到“是”：罕见病患者及家属权益倡导中的价值彰显
Am J Bioeth. 2021 Dec;21(12):1-3. doi: 10.1080/15265161.2021.1996801.
2
Advocacy for persons with rare diseases: a strategy for creating influence.为罕见病患者发声：一种创造影响力的策略。
Nat Clin Pract Rheumatol. 2007 Aug;3(8):421. doi: 10.1038/ncprheum0561.
3
Reliance on Advocacy is the Symptom Not the Disease.依赖宣传是症状而非疾病。
Am J Bioeth. 2023 Jul;23(7):86-88. doi: 10.1080/15265161.2023.2207540.
4
Cross-border rare disease advocacy: Preethi Krishnaraj interviews Harsha Rajasimha.跨境罕见病宣传：普里蒂·克里希纳拉杰采访哈莎·拉贾西姆哈。
Dis Model Mech. 2024 Jun 1;17(6). doi: 10.1242/dmm.050672. Epub 2024 Jan 25.
5
[Ethics and rare diseases].[伦理与罕见病]
Soins. 2003 Jan-Feb(672):37-9.
6
Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases.与生物制药公司互动的原则：为罕见病领域的患者倡导组织制定指南。
Orphanet J Rare Dis. 2018 Jan 22;13(1):18. doi: 10.1186/s13023-018-0761-2.
7
Patient advocacy in Diamond Blackfan anemia: facilitating translational research and progress towards the cure of a rare disease.钻石黑范贫血中的患者权益倡导：促进转化研究及罕见病治愈进展
Semin Hematol. 2011 Apr;48(2):75-80. doi: 10.1053/j.seminhematol.2011.01.001.
8
Advocacy groups and their role in rare diseases research.倡导组织及其在罕见病研究中的作用。
Adv Exp Med Biol. 2010;686:515-25. doi: 10.1007/978-90-481-9485-8_28.
9
The evolving role of patient advocates in rare cancers: opportunities and challenges.患者倡导者在罕见癌症中不断演变的角色：机遇与挑战。
Expert Rev Pharmacoecon Outcomes Res. 2019 Feb;19(1):1-3. doi: 10.1080/14737167.2019.1526083. Epub 2018 Sep 27.
10
Informed consent and patient registry for the rare disease community: Editorial.罕见病群体的知情同意与患者登记：编者按
Contemp Clin Trials. 2012 Jan;33(1):3-4. doi: 10.1016/j.cct.2011.10.005. Epub 2011 Oct 22.

引用本文的文献

1
Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence.英国患者组织的行业资助：商业决定因素、资金集中和疾病流行情况的回顾性研究。
BMJ Open. 2023 Jun 27;13(6):e071138. doi: 10.1136/bmjopen-2022-071138.
2
Reliance on Advocacy is the Symptom Not the Disease.依赖宣传是症状而非疾病。
Am J Bioeth. 2023 Jul;23(7):86-88. doi: 10.1080/15265161.2023.2207540.
3
Rare Disease, Advocacy and Justice: Intersecting Disparities in Research and Clinical Care.罕见病、倡导和正义：研究和临床护理中的交叉差异。
Am J Bioeth. 2023 Jul;23(7):17-26. doi: 10.1080/15265161.2023.2207500. Epub 2023 May 19.
4
Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab.追求加速审批的合理性：预测并避免下一个 aducanumab。
Drugs Aging. 2022 Jun;39(6):389-400. doi: 10.1007/s40266-022-00949-8. Epub 2022 Jun 13.

本文引用的文献

1
Another Cautionary Lesson from COVID Research.来自新冠研究的另一个警示教训。
Am J Bioeth. 2021 Dec;21(12):36-39. doi: 10.1080/15265161.2021.1991048.
2
Physician Responsibility to Discuss Palliative Unproven Therapies With Out-of-Option Patients.医生有责任与别无选择的患者讨论姑息性未经证实的疗法。
Am J Bioeth. 2021 Dec;21(12):31-33. doi: 10.1080/15265161.2021.1991038.
3
Decisions on Innovation or Research for Devastating Disease.关于毁灭性疾病创新或研究的决策。
Am J Bioeth. 2021 Dec;21(12):28-31. doi: 10.1080/15265161.2021.1991042.
4
Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?有益的经验教训和警示故事：COVID-19 药物研发和获取如何为非大流行疾病的方法提供信息？
Am J Bioeth. 2021 Dec;21(12):4-19. doi: 10.1080/15265161.2021.1974975. Epub 2021 Oct 19.
5
"It seems like COVID-19 now is the only disease present on Earth": living with a rare or undiagnosed disease during the COVID-19 pandemic.“似乎现在地球上只有 COVID-19 一种疾病”：在 COVID-19 大流行期间患有罕见或未确诊疾病的生活。
Genet Med. 2021 May;23(5):837-844. doi: 10.1038/s41436-020-01069-7. Epub 2021 Jan 8.
6
Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways.促进证据与可及性：改进美国食品药品监督管理局的加速批准和扩大可及途径
J Law Med Ethics. 2020 Jun;48(2):365-372. doi: 10.1177/1073110520935352.
7
Civic Engagement, Autism and Deliberative Democracy: Prioritizing the Inclusion of Marginalized Perspectives.公民参与、自闭症与协商民主：优先纳入边缘化观点
Am J Bioeth. 2020 May;20(4):41-43. doi: 10.1080/15265161.2020.1730620.
8
Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.联邦“试用权”立法——对美国食品药品监督管理局公共卫生使命的威胁。
N Engl J Med. 2018 Feb 22;378(8):695-697. doi: 10.1056/NEJMp1714054. Epub 2018 Jan 10.
9
Which orphans will find a home? The rule of rescue in resource allocation for rare diseases.哪些孤儿能找到归宿？罕见病资源分配中的救援原则。
Hastings Cent Rep. 2012 Jan-Feb;42(1):27-34. doi: 10.1002/hast.12.
10
Advocacy groups and their role in rare diseases research.倡导组织及其在罕见病研究中的作用。
Adv Exp Med Biol. 2010;686:515-25. doi: 10.1007/978-90-481-9485-8_28.

From "Ought" to "Is": Surfacing Values in Patient and Family Advocacy in Rare Diseases.

作者信息

Halley Meghan C

机构信息

Stanford University School of Medicine.

出版信息

Am J Bioeth. 2021 Dec;21(12):1-3. doi: 10.1080/15265161.2021.1996801.

DOI:10.1080/15265161.2021.1996801
PMID:34806973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8725198/
Abstract
摘要